- Home
- NX vs SNDX Comparison
NX vs SNDX Comparison
Compare NX & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NX
- SNDX
- Stock Information
- Founded
- NX 1927
- SNDX 2005
- Country
- NX United States
- SNDX United States
- Employees
- NX N/A
- SNDX N/A
- Industry
- NX Metal Fabrications
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- NX Industrials
- SNDX Health Care
- Exchange
- NX Nasdaq
- SNDX Nasdaq
- Market Cap
- NX 1.1B
- SNDX 1.2B
- IPO Year
- NX N/A
- SNDX 2016
- Fundamental
- Price
- NX $18.61
- SNDX $12.29
- Analyst Decision
- NX Strong Buy
- SNDX Strong Buy
- Analyst Count
- NX 1
- SNDX 10
- Target Price
- NX $38.00
- SNDX $36.20
- AVG Volume (30 Days)
- NX 592.3K
- SNDX 1.7M
- Earning Date
- NX 03-10-2025
- SNDX 03-03-2025
- Dividend Yield
- NX 1.72%
- SNDX N/A
- EPS Growth
- NX N/A
- SNDX N/A
- EPS
- NX 0.29
- SNDX N/A
- Revenue
- NX $1,438,751,000.00
- SNDX $23,680,000.00
- Revenue This Year
- NX $49.00
- SNDX $274.86
- Revenue Next Year
- NX $2.89
- SNDX $130.47
- P/E Ratio
- NX $64.10
- SNDX N/A
- Revenue Growth
- NX 29.87
- SNDX N/A
- 52 Week Low
- NX $18.14
- SNDX $12.06
- 52 Week High
- NX $38.98
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- NX 37.33
- SNDX 37.03
- Support Level
- NX $19.53
- SNDX $12.70
- Resistance Level
- NX $20.47
- SNDX $13.80
- Average True Range (ATR)
- NX 0.69
- SNDX 0.66
- MACD
- NX 0.01
- SNDX -0.03
- Stochastic Oscillator
- NX 16.73
- SNDX 7.60
About NX Quanex Building Products Corporation
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its three operating segments are North American Fenestration being the key revenue driver, European Fenestration, and North American Cabinet Components. Geographically, it derives a majority of revenue from the United States.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.